Growth Fund Sells $20 Million in Novanta Stock as Headwinds Weigh on Returns

Conestoga Capital Advisors reduced its stake in Novanta (NASDAQ:NOVT) during Q3, selling 168,907 shares for an estimated $20.1 million, bringing its holding to 2.3% of its U.S. equity AUM. This divestment reflects Conestoga's frustration with Novanta's 26% stock underperformance over the past year and broader sector headwinds, despite the firm maintaining long-term conviction in the company's fundamentals. The move follows Novanta's flat Q2 organic growth and declining GAAP profit, suggesting that future institutional interest will likely hinge on the company's ability to reignite growth.

Analysis

Conestoga Capital Advisors reduced its Novanta (NOVT) stake by 168,907 shares, an estimated $20.1 million transaction, during the third quarter. This divestment, representing 0.3% of Conestoga’s 13F AUM, leaves Novanta as 2.3% of their U.S. equity assets. The move coincides with Novanta's significant stock underperformance, down 26% over the past year, vastly trailing the S&P 500's nearly 17% gain.

The sale reflects Conestoga's frustration with Novanta's weak relative performance and sector headwinds, rather than a loss of conviction in the company's fundamentals. Novanta's second-quarter results showed flat organic growth and a sharp GAAP profit decline to $4.5 million from $13.8 million year-over-year, though adjusted earnings held steady at $0.76 per share. This operational stagnation, alongside broader market preferences for cyclical and semiconductor names, contributed to the stock's drag on Conestoga's returns.

Novanta's core business in photonics, vision, and precision motion for medical and industrial OEMs remains aligned with secular growth themes in medical imaging and robotics. The company leverages a diversified portfolio of proprietary technologies to address complex application needs globally. However, the ability to reignite organic growth will be the critical factor determining whether institutional investors rebuild their positions.

Key Decisions for Investors

• Investors should closely monitor Novanta's upcoming earnings reports for signs of re-accelerated organic growth, which is crucial for renewed institutional interest.
• Consider the partial divestment by Conestoga as a potential short-term rotation driven by recent underperformance and sector dynamics, rather than a complete loss of long-term fundamental conviction.
• Evaluate Novanta's long-term strategic alignment with secular growth themes in medical and industrial automation against its recent operational challenges and stock price weakness.